ResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022

SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2023 on Thursday, October 27, 2022, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.

Earnings webcast details:

•		Location:	http://investor.resmed.com
•		Date:	Thursday, October 27, 2022
•		Time:	1:30 p.m. PDT / 4:30 p.m. EDT
•		International:	London, Thursday, October 27, 9:30 p.m. BST
			Sydney, Friday, October 28, 7:30 a.m. AEDT

Please note that ResMed does not use outside phone lines to access the earnings call.

A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible from October 27 until November 10 at:

•		U.S.: +1 877.660.6853
•		International: +1 201.612.7415
•		Conference ID: 13733726

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

For investors Amy Wakeham +1 858.836.5000 investorrelations@resmed.com

For media Jayme Rubenstein +1 858.836.6798 news@resmed.com